Sign In
Buy PEN
$319.37
+0.630 (+0.198%)
At Close: Jun 03, 2026
3 Reasons Growth Investors Will Love Penumbra (PEN)
01:45pm, Monday, 28'th Apr 2025
Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Why Penumbra (PEN) is a Top Growth Stock for the Long-Term
10:50am, Monday, 28'th Apr 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Penumbra Among Well-Insulated Companies From Ongoing Tariff Dynamics, Says Analyst
03:27pm, Thursday, 24'th Apr 2025
Penumbra Inc PEN stock is trading higher after the company reported better-than-expected first-quarter 2025 earnings and reaffirmed the 2025 forecast.
Penumbra Q1 Earnings & Revenues Top Estimates, Stock Up, Margins Expand
11:45am, Thursday, 24'th Apr 2025
PEN reports better-than-expected earnings and revenues in the first quarter of 2025.
Penumbra, Inc. (PEN) Q1 2025 Earnings Call Transcript
08:15pm, Wednesday, 23'rd Apr 2025
Penumbra, Inc. (NYSE:PEN ) Q1 2025 Earnings Conference Call April 23, 2025 4:30 PM ET Company Participants Cecilia Furlong - Business Development & IR Adam Elsesser - Chairman & CEO Maggie Yuen - CFO
Penumbra (PEN) Reports Q1 Earnings: What Key Metrics Have to Say
07:00pm, Wednesday, 23'rd Apr 2025
The headline numbers for Penumbra (PEN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimate
Penumbra (PEN) Q1 Earnings and Revenues Top Estimates
06:15pm, Wednesday, 23'rd Apr 2025
Penumbra (PEN) came out with quarterly earnings of $0.83 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.41 per share a year ago.
Penumbra, Inc. Reports First Quarter 2025 Financial Results
04:05pm, Wednesday, 23'rd Apr 2025
ALAMEDA, Calif. , April 23, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2025.
PHILADELPHIA, April 21, 2025 (GLOBE NEWSWIRE) -- The law firm of Kaskela Law LLC is investigating Penumbra, Inc. (NYSE: PEN) on behalf of the company's current shareholders.
Why Penumbra (PEN) is Poised to Beat Earnings Estimates Again
01:15pm, Monday, 21'st Apr 2025
Penumbra (PEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Penumbra (PEN) Earnings Expected to Grow: Should You Buy?
11:06am, Wednesday, 16'th Apr 2025
Penumbra (PEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Reasons to Retain Penumbra Stock in Your Portfolio for Now
11:00am, Tuesday, 08'th Apr 2025
PEN continues to attract investor interest with its strong Thrombectomy business and portfolio expansion efforts.
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Penumbra, Inc. (NYSE: PEN)
08:00am, Tuesday, 08'th Apr 2025
NEW YORK , April 8, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Penumbra, Inc. (NYSE: PEN) on behalf of the company's shareholders. The investigation seeks to det
Penumbra, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for April 23, 2025
04:30pm, Thursday, 03'rd Apr 2025
ALAMEDA, Calif. , April 3, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2025 after market clos
ALAMEDA, Calif. , April 2, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced seven significant computer assisted vacuum thrombectomy (CAVT™) data p
